Week in Review: Preserving What Works

06.14.13 | By

The first step toward finding solutions in our health care ecosystem is to identify what works, protect what is successful and fix what isn’t. This includes access to medicines, continued research and development and developing programs that get patients the treatments they need.

Castellani Highlights Part D’s Success in Hill Blog

06.14.13 | By

Craving some health policy news on a Friday afternoon? Check out an op-ed that ran in The Hill today from our CEO, John Castellani, on Part D.

Two Key Steps in Elevating Biopharmaceutical Science

06.14.13 | By

Science has been on my mind lately – and for two very good reasons.

PDUFA/FDASIA Implementation Update

06.13.13 | By

As you may know from reading past Catalyst posts, the Prescription Drug User Fee Act (PDUFA) was reauthorized last July when the Food and Drug Safety and Innovation Act (FDASIA) was signed into law.

Part D Preserves Access to Medicines for Beneficiaries with Diabetes

06.12.13 | By

The Annals of Internal Medicine recently published a study that compared prescription diabetes medicine use between Medicare Part D and the Veterans Affairs (VA) program, specifically focusing on generic drug use. The study and subsequent media coverage overlook some important facts about prescription drug coverage in these two programs.

Adhering to Heart Health

06.12.13 | By

Every 39 seconds an American dies from cardiovascular disease, and more than 83 million Americans have at least one type of the disease, the American Heart Association (AHA) reports. But today, America’s biopharmaceutical research companies are developing 215 medicines for two of the leading causes of death of Americans – heart disease and stroke. 

More Than 200 Innovative Medicines in Development For Heart Disease and Stroke

WASHINGTON, D.C. (June 12, 2013) – America’s biopharmaceutical research companies are developing 215 medicines for two of the leading causes of death of Americans – heart disease and stroke, according to a new report and overview released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Week in Review: Innovation Provides Value for Patients…And Everyone Else, Too

06.07.13 | By

Medical innovation does an enormous amount of good for patients, but there is also a broader societal impact: innovative research positively impacts the economy, as well.

U.S. Policymakers Can’t Ignore Storm Clouds from India

06.07.13 | By

This week, the Commerce Department released the latest data on America’s trade balance, and the news was not good. While exports of U.S. goods and services rose in April, our trade deficit grew to $40.3 billion, up more than 8 percent in a single month.

PhRMA Statement on Sequestration of PDUFA User Fees

WASHINGTON, D.C. (June 7, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Scientific and Regulatory Affairs Sascha Haverfield, Ph.D., issued the following statement today:

“PhRMA remains deeply concerned about the impact of sequestration on the Food and Drug Administration’s (FDA) ability to fulfill its critical public health mission by fostering timely patient access to safe and effective new medicines. 


Subscribe to RSS - Opinion